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Neonatal Diabetes (ND) mellitus is a rare genetic disease (1 in 90,000 live births). It is
defined by the presence of severe hyperglycaemia associated with insufficient or no
circulating insulin, occurring mainly before 6 months of age and rarely between 6 months
and 1 year. Such hyperglycaemia requires either transient treatment with insulin in about
half of cases, or permanent insulin treatment. The disease is explained by two major
groups of mechanism: malformation of the pancreas with altered insulin-secreting cells
development/survival or abnormal function of the existing pancreatic β cell. The most
frequent genetic causes of neonatal diabetes mellitus with abnormal β cell function
are abnormalities of the 6q24 locus and mutations of the ABCC8 or KCNJ11 genes
coding for the potassium channel in the pancreatic β cell. Other genes are associated
with pancreas malformation or insufficient β cells development or destruction of β cells.
Clinically, compared to patients with an ABCC8 or KCNJ11 mutation, patients with a
6q24 abnormality have lower birth weight and height, are younger at diagnosis and
remission, and have a higher malformation frequency. Patients with an ABCC8 or
KCNJ11mutation have neurological and neuropsychological disorders in all those tested
carefully. Up to 86% of patients who go into remission have recurrent diabetes when they
reach puberty, with no difference due to the genetic origin. All these results reinforce the
importance of prolonged follow-up by amultidisciplinary pediatric team, and later doctors
specializing in adult medicine. 90% of the patients with an ABCC8 or KCNJ11 mutation
as well as those with 6q24 anomalies are amenable to a successful switch from insulin
injection to oral sulfonylureas.
Keywords: neonatal diabetes mellitus, chromosome 6q24 abnormality, associated malformations,
neuropsychological disorder, KCNJ11 (Kir6.2), ABCC8, sulfonylurea receptor (SUR1)
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DEFINITION
Diabetes mellitus in very young children or neonatal diabetes
is a rare genetic disease (minimal incidence: 1 in 90,000 live
births) with variations within different ethnic groups (1–3). It
is defined by the presence of severe hyperglycaemia requiring
treatment and occurs between the neonatal period and infancy.
It occurs mainly before 6 months of age (155/173 probands
in our published cohort) and rarely between 6 months and 1
year (18/173) (4). In the Finnish population for example, after
6 months of age, patients with diabetes had high HLA risk
genotypes and islet autoantibodies, reflecting the autoimmune
character of diabetes (5). This hyperglycaemia is associated with
insufficient or no circulating insulin (3). Two clinical forms have
been distinguished, based on the duration of the treatment: a so
called “transient form” and a permanent form.
The disease is explained by two major groups of mechanism:
malformation of the pancreas or abnormal function of the
pancreatic β cell that secretes insulin (by poor insulin cell
mass development or malfunction of a cell component or by
destruction of the β cell) (Table 1) (see Figure 1 for the normal
functioning of the β cell).
GENETIC CAUSES
Abnormal β Cell Function
The most frequent genetic causes of neonatal diabetes with
normal pancreas morphology are abnormalities of the 6q24
locus and mutations of the genes coding for the ATP-dependent
potassium channel.
6q24 (MIM#601410 and 603044)
The first genetic causes identified were abnormalities of the
6q24 locus, which include paternal uniparental disomy of 6q24
(pUPD6), partial duplication of paternal 6q24 and relaxation
of the maternal 6q24 imprinted locus. This locus contains
a CpG island, presenting differential methylation depending
on the parental origin (non-methylation on the paternal
allele, methylation on the maternal allele) (6). To date, the
methylation abnormality has not been found in the parents of
affected children. Methylation is used to down-regulate gene
transcription of themethylated allele. All these abnormalities lead
to over-expression of imprinted genes located in 6q24, such as
PLAGL1/ZAC (pleiomorphic adenoma gene-like 1) and HYMAI
(Hydatidiform mole-associated and imprinted transcript), which
are the most “likely” candidate genes (6–8). PLAGL-1 codes for
a transcription factor involved in regulation of stopping the cell
cycle and apoptosis and in induction of the receptor 1 gene
for human pituitary adenylate cyclase-activating polypeptide
(PACAP1, which is a potent stimulant of insulin secretion). The
function of the HYMAI gene is unknown (9). The mechanism
responsible for the diabetes could be linked to a developmental
defect in the β cells but the fact that remission of the diabetes
occurs means that an abnormality in β cell function cannot
be ruled out (10). The 6q24 abnormalities are associated with
“transient” neonatal diabetes (7, 8, 11).
The ZFP57 gene (MIM ∗612192) is involved in maintaining
methylation of the DNA during the very early stages of
embryogenesis. It is localized at 6p22.1. Homozygous mutations
leading to a lack of protein or non-functional protein are
associated with widespread DNA hypomethylation, including
hypomethylation of the 6q24 locus (12). However, there are
patients who have a 6q24 methylation abnormality not due to
mutations of this gene (12).
Mutations of the ABCC8 and KCNJ11 Genes Coding
for the KATP Channel: (MIM
∗600509 and ∗600937)
The ATP-dependent potassium channel (KATP channel) plays a
central role in stimulating insulin secretion by the pancreatic
β cell in response to glucose. At low blood sugar levels
(e.g., fasting), the KATP channels are open (activated) and
their activity maintains a hyperpolarized resting membrane
potential (around −70mV). A rise in blood sugar level (e.g.,
post-prandial) causes increased passage of glucose into the β
cell. Glucose enters the glycolysis pathway, which increases
the intracellular ATP concentration. This causes the KATP
channels to close (inhibition), which leads to the intracellular
potassium accumulation that causes membrane depolarization.
This depolarization activates the voltage-dependent calcium
channels, leading to Ca2+ ions entering the β cell, then enabling
exocytosis of the secretion vesicles and release of insulin into the
bloodstream (Figure 1).
The KATP channel is an octamer formed from two types of
subunits: the Kir6.2 subunits form the channel selective for the
incoming corrective potassium enclosed in SUR1 ion-channel
regulator subunits (13, 14). They are coded by the KCNJ11 and
ABCC8 genes, respectively.
Activating mutations in one of these two genes are responsible
for neonatal diabetes with normal pancreas morphology (15–17).
They result in the KATP channel remaining permanently open,
so that it no longer controls membrane potential in response
to glucose and therefore blocks the event cascade that leads to
insulin release.
Mutations of the Insulin Gene (INS) (MIM ∗176730)
The third cause of neonatal diabetes, by frequency, is mutations
of the insulin gene (INS). The majority are heterozygous
mutations affecting the structure of preproinsulin; these are
transmitted in an autosomal dominant manner (18, 19). The
abnormal proinsulin undergoes degradation in the endoplasmic
reticulum, leading to severe endoplasmic reticulum (ER) stress
and β cell death. This process has been described in mouse
models (20) and in man (21, 22). Recent evidence suggests that
INS mutations do not necessarily lead to beta-cell death but
rather the chronic ER stress interferes with beta-cell growth and
development (23).
Some mutations alter expression of the protein. They are
transmitted in a recessive manner, in the majority of cases
in consanguineous families. These mutations affect the insulin
promoter directly of by mutation in factor that enhances its
activity (24, 25).
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TABLE 1 | Genetic causes of monogenic neonatal diabetes based on physiopathological mechanisms [excluding 6q24 locus abnormalities (MIM *601410,
*603044, and *612192)].
Gene/Protein Function Locus Transmission mode Type of diabetes Reference
OMIM numbers
BETA CELL FUNCTION ABNORMALITY
ABCC8/SUR1 KATP channel/insulin
secretion
11p15.1 Dominant PND/TND/iDEND/DEND MIM *600509
KCNJ11/Kir6.2 KATP channel/insulin
secretion
11p15.1 Dominant PND/TND/iDEND/DEND MIM *600937
INS/Insulin Hormone 11p15.5 Rare Recessive Isolated TND/PND MIM *176730
GCK/Glucokinase Glucose metabolism 7p15.3-p15.1 Recessive/Dominant Heterozygous: MODY2
Homozygous: PND
MIM *138079
SLC2A2/GLUT2 Membrane receptor 3q26.1-q26.2 Recessive PND/TND + Fanconi-Bickel
syndrome (glycogenosis)
Proximal tubulopathy + small size +
rickets + abnormality of glucose and
galactose metabolism
MIM *138160
SLC19A2 Thiamine transporter 1q23.3 Recessive Rogers Syndrome: Thiamine-sensitive
megaloblastic anemia + diabetes +
perceptive deafness ± PND
MIM *603941
ENDOCRINE PANCREAS DEVELOPMENT ABNORMALITY
GATA6/GATA6 Transcription factor 18q11.1-q11.2 Dominant PND by pancreas
agenesis/hypoplasia + congenital





Transcription factor 9p24.2 Recessive PND + congenital hypothyroidism ±
progressive hepatic fibrosis ± cystic
renal dysplasia ± congenital
glaucoma
MIM *610192
HNF1β/HNF1β Transcription factor 17q12 Dominant MODY5 or TND + pancreatic
hypoplasia + renal cyst
MIM *189907
NEUROD1/BETA2 Transcription factor 2q31.3 Recessive/Dominant Heterozygous: MODY6
Homozygous: PND + cerebellar
hypoplasia + visual defect +
perceptive deafness
MIM *601724
NEUROG3/Neurogenin3 Transcription factor 10q21.3 Recessive Homozygous hypomorphic mutation:
congenital malabsorption diarrhea +





PAX6/aniridia type II protein,
Pax6






Transcription factor 13q12.1 Recessive/Dominant Heterozygous: MODY4
Homozygous nonsense mutation:
PND by agenesis/hypoplasia of the
pancreas
Homozygous hypomorphic mutation:




Transcription factor 10p12.2 Recessive PND by agenesis of the pancreas +
cerebellar agenesis
MIM *607194
RFX6/Rfx6 Transcription factor 6q22.1 Recessive Martinez-Frias Syndrome: Pancreatic
hypoplasia + intestinal atresia with
diarrhea + agenesis/hypoplasia of the
gall bladder
MIM *612659
CNOT1 Transcriptional repressor 16q21 De novo specific
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TABLE 1 | Continued
Gene/Protein Function Locus Transmission mode Type of diabetes Reference
OMIM numbers
DESTRUCTION/ENDOPLASMIC RETICULUM STRESS WITH LOW INSULIN CELL MASS OR DESTRUCTION OR EARLY IMMUNE DESTRUCTION
OF THE BETA CELLS
INS/Insulin Hormone 11p15.5 Dominant PND MIM *176730















Xp11.23 X-linked recessive IPEX syndrome:
Immunodysregulation
Polyendocrinopathy Enteropathy
X-linked: PND + increased IgE levels
MIM *300292
STAT3 Transcription factor 17q21.2 Dominant Autoimmune disease, multisystem
PND
MIM *102582
WFS1/Wolframin Transmembrane protein of
the endoplasmic reticulum
4p16.1 Recessive Wolfram Syndrome: PND + optic
atrophy ± diabetes insipidus ±
deafness (DIDMOAD)
MIM *222300
ND, neonatal diabetes; PND, permanent neonatal diabetes; TND, transient neonatal diabetes; DEND, Developmental delay, Epilepsy and Neonatal Diabetes; iDEND, intermediate DEND
= DEND without epilepsy; MODY, Maturity Onset Diabetes of the Young.
FIGURE 1 | Mechanism of insulin secretion in response to glucose and glibenclamide.
Mutations of the Glucokinase Gene (MIM ∗138079)
Glucokinase is responsible for the first step of glucosemetabolism
in the β cell. It acts as a “sensor” of blood glucose, making it
possible to control the quantity of insulin secreted. Nonsense
mutations of the glucokinase gene cause MODY 2 (Maturity
onset diabetes in the youth type 2), which usually presents as
moderate hyperglycaemia (26). Transmission is heterozygous.
In the homozygous state, these nonsense mutations cause
neonatal diabetes by complete deficiency of glucokinase-
mediated glycolysis (27). This is not a frequent cause of neonatal
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diabetes (28, 29). However, an assay of the fasting blood glucose
concentration is required from both parents, particularly if there
is a history of gestational diabetes. The discovery of discreet
glucose intolerance in both parents should therefore lead to a
search for glucokinase gene mutations.
Abnormal Pancreas Morphology
Several genes are linked to neonatal diabetes with abnormal
pancreasmorphology and precise description is beyond the scope
of this chapter (see Table 1 for a brief information). These genes
are involved in development of the pancreas at various stages
in early morphogenesis. These neonatal diabetes cases may be
associated with a deficiency of the exocrine pancreas, based
on the severity of pancreatic damage or to other congenital
malformations. Mutation of the RFX-6 gene deserves a specific
comment. The RFX-6 transcription factor is involved in the
differentiation of beta-cells in the pancreas during embryonic
development of the pancreas. It is also expressed in mature
cells where it has a role in regulating insulin transcription and
secretion. It actually controls the expression and activation of
calcium channels and its inactivation alters insulin secretion in
response to glucose. A few cases of neonatal diabetes have been
reported. Patients display developmental abnormalities of the
pancreas and of the digestive tract. The mechanism is linked to
both a developmental and a functional disorder of the endocrine
pancreas. Transmission is autosomal recessive (Table 1).
Autoimmune Neonatal Diabetes Mellitus
Most patients diagnosed with diabetes between 6 and 12 months
of age will have the “typical” type 1 diabetes mellitus seen in
older children with positive autoantibodies against the beta cell.
Autoimmune diabetes is very rare before 6months of age and will
most often be linked to specific causes.
IPEX Syndrome (Table 1)
Mutations of the FOXP3 gene may be responsible for
enteropathy, immune dysregulation and polyendocrinopathy.
It is a cause of neonatal diabetes associated with early
autoimmunity directed against the beta cells of the pancreas.
This diagnosis should be considered in male infants presenting
diabetes associated with immune deficiency and/or severe
infections. Immunosuppressant treatment can be considered
(serolimus, corticosteroids) but bone marrow transplant must
be considered as soon as the child’s clinical condition allows.
Insulin treatment will be combined with specialized nutritional
management (parenteral ± enteral nutrition) before and after
the transplant. It should be noted that, while correcting immune
deficiencies, this will not eliminate the diabetes.
Down Syndrome and Neonatal Diabetes
Patients with Down syndrome (DS) resulting from trisomy 21
are more likely to have childhood diabetes mellitus. Professor
Hattersley’s group found 13 infants affected by DS who were
diagnosed with diabetes before the age of 6 months. Trisomy 21
was seven times more likely in their PNDM cohort than in the
general population (13 of 1,522 = 85 of 10,000 observed vs. 12.6
of 10,000 expected). Known PNDM genes explains 82.9% of non-
DS PNDM in their work. None of the 13 DS-PNDM patients had
a mutation in those genes. The conclusion from this work is that
trisomy 21 is a cause of autoimmune PNDM that is not HLA
associated (30).
Other mutations, such as the activating STAT3mutations have
been described which cause neonatal diabetes associated with
beta-cell autoimmunity (Table 1).
CLINICAL DESCRIPTION
There are two clinical forms of neonatal diabetes based on the
duration of insulin-dependency. In the transient form, treatment
may be stopped at any time from the first weeks of life to 5 years of
age (4). In the permanent forms, life-long treatment is necessary.
The clinical difference between transient and permanent
neonatal diabetes is not always underpinned by distinct
molecular mechanisms. Abnormalities of the 6q24 locus are
exclusively linked to transient neonatal diabetes. However,
mutations of the ABCC8, KCNJ11, and INS genes are linked to
both permanent and transient forms (17, 18, 25). Other genetic
causes are associated with permanent neonatal diabetes.
Neonatal diabetes is usually diagnosed before 6 months of age.
However, the age of diagnosis varies depending on genetic causes:
diabetes due to a 6q24 locus abnormality appears before the age
of 1 month in 93% of cases and before the age of 3 months in
100% of cases. In ABCC8 and KCNJ11 gene mutations, it appears
before the age of 1 month in 30% of cases and between 1 and 6
months in 66% of cases (4).
At birth, patients have a birth-weight below the 10th percentile
in 62% of cases (4), highlighting the crucial role of insulin
secretion in fetal growth. This intrauterine growth retardation is
found in all genetic groups with a greater proportion in patients
with a 6q24 abnormality than those carrying aABCC8 orKCNJ11
mutation (92 vs. 48%, p < 0.001) (4).
Half of patients with a detectable pancreas by ultrasound
experience remission from the diabetes in our cohort (4). This
occurs at the age of about 4 months. There is a difference
depending on the genetic cause. Patients with a 6q24 locus
abnormality are in remission before the age of 1 year in 97% of
cases (median age 14 weeks) while remission may go as far as the
age of 5 years in patients with an ABCC8 or KCNJ11 mutation
(median age 39 weeks) (4, 31). Patients with a rare recessive
mutation of the INS gene have remission at a median age of
12 weeks (24), whereas the majority of the INS gene mutations
are dominant and they never go into remission. The diabetes
frequently relapses (in up to 86% of cases) at the onset of puberty,
probably due to the insulin resistance of puberty (4, 32). There is
no difference between the genetic groups.
Depending on the genetic cause, patients with neonatal
diabetes may have other clinical signs associated with
diabetes (Table 1).
In neonatal diabetes with normal pancreas morphology,
there are associated neurological disorders and developmental
defects. Approximately 25% of patients with a mutation of
the ABCC8 or KCNJ11 genes have neurological disorders
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ranging from psychomotor disorders to delayed cognitive
development associated with severe epilepsy (DEND syndrome:
Developmental delay, Epilepsy, and Neonatal Diabetes) (33). In
addition, we have shown that when patients undergo detailed
neuro-psychomotor and neuropsychological tests, an attention
deficit or language disorder extending as far as dyslexia is found
in 100% of cases (4).
Patients with a 6q24 locus abnormality may have
developmental defects (macroglossia, umbilical hernia,
cardiac malformations, renal and urinary malformations,
non-autoimmune anemia, hypothyroidism with gland in situ)
and neurological disorders (4, 11).
In neonatal diabetes with abnormal pancreas morphology or
with β cell destruction, the associated malformations depend
on the genetic causes and are often grouped into defined
syndromes (Table 1). Figure 2 illustrates a diagnostic strategy by
molecular biology.
Recent long-term follow-up data in TNDM support a decrease
in maximal insulin secretion capacity to both glucose and
arginine stimuli that reflect low insulin mass (34). This study also
showed that, regardless of the underlying genetic abnormalities
or the duration of diabetes, TNDM was associated with learning
difficulties at school. The high relapse rate and absence of
identified predictors of relapse in TNDM suggest a need for an
HbA1c assay at least every 2 years throughout childhood and
for an HbA1c assay and oral glucose tolerance test every year
throughout adolescence (34). During childhood, close attention
should be directed to education and neurodevelopmental
milestones, in TNDM patients with and without diabetes (34).
THERAPEUTIC ASPECTS
Drug Treatment
Due to the early onset and associated delayed intrauterine
retardation, patients with neonatal diabetes very often receive
their initial treatment in a neonatal department. The initial
treatment aims to rebalance carbohydrate metabolism. It should
be started immediately following diagnosis. The treatment
consists of the balance between a calorie and carbohydrate
intake necessary to restore normal weight without being excessive
to avoid the risk of future insulin resistance (15–18 g/kg/d
carbohydrate) and sufficient insulin-based treatment to achieve
the correct metabolic equilibrium. Restricting intake below
the nutritional recommendations for children with low birth
weight is ineffective given the physiopathology of circulating
insulin deficiency.
Insulin-based treatment is difficult to manage due to the very
low weight. The therapeutic margins between hypoglycemia and
hyperglycemia are small, and both are harmful for neurological
development of the newborn. Using an insulin pump with
or without dilution of the insulin to 1:10 in 0.9% NaCl
(or with a bona-fide diluent if available) can sometimes improve
manageability of the insulin during the first weeks of life (35, 36).
Blood glucose meters must be able to give a reliable measurement
of capillary blood sugar level with the smallest possible quantity
of blood (e.g., 0.3 µl blood). Few “conventional” blood glucose
meters meet this criterion. Conventional capillary measurements
can be done on the side edge of all the fingers, using auto-lancets
offering variable pricking depths. This offers the advantage of
sparing newborns’ heels. An alternative is to use continuous
glucose sensors, either isolated or combined with an insulin
pump. In addition to enabling rapid access to interstitial blood
glucose (they provide a proxy but do not actually measure the
blood glucose value), they can now be coupled to the insulin
pump,making it possible to activate the system to stop the insulin
pump during hypoglycemia or before it occurs. They also have
the advantage of minimizing the number of pricks of the skin.
Used under suitable hygiene conditions, there is no increase in
skin infections. It is advisable to involve experienced clinicians
when treating the child and using these techniques.
Patients with ABCC8 or KCNJ11 mutations are treated
successfully using hypoglycemic sulfonylureas, which act by
binding to the regulator SUR1 subunit of the potassium
channel (37) (Figure 1). The mutated channels remain sensitive
to sulfonylureas in 90% of cases, having an inhibitory
effect on the potassium channel of the pancreatic β cell
and restoring insulin secretion in response to a meal (38).
Sulfonylurea therapy appears to be safe and often successful
in neonatal diabetes patients before genetic testing results are
available (39). An empiric inpatient trial of sulfonylurea can
be therefore considered (39). However, obtaining a genetic
diagnosis remains imperative to inform long-term management
and prognosis.
It has now been demonstrated that treatment with
Sulfonylureas provide a better metabolic equilibrium than
insulin by normalizing the HbA1c while strongly reducing
the incidence of hypoglycemia in cases of neonatal diabetes
with ABCC8 or KCNJ11 mutations. It was also shown recently
that hypoglycemic sulphonylureas were able to improve
neurological, neuropsychological and visuomotor impairment if
they are introduced early in the child’s life (33, 40, 41). Finally,
a recent study has shown that it could sometimes be used
successfully to replace insulin in neonatal diabetes associated
with chromosome 6 methylation abnormalities (42). This
emphasizes the importance of making a genetic diagnosis rapidly
after diagnosing neonatal diabetes, and especially the early
introduction of sulphonylureas. The clinician’s aim will be to
treat the child with the maximum dose that normalizes blood
glucose levels (pre-prandial target: 70–120mg/dL—post-prandial
target: 100–145 mg/dL) without causing hypoglycemia, in order
to optimize the drug’s effect on the central nervous system.
Sulphonylureas are currently only available as a 5mg tablet and
are not licensed for indications in neonatal diabetes. However,
glibenclamide has recently obtained the orphan-drug indication
from the European Medicine Agency (EMA) in neonatal
diabetes. Unlicensed administration is currently achieved by
parents through crushing and extemporaneous dilution of
the tablets. However, the crushed tablets are poorly soluble
in water, which may lead to variations in the dosage actually
received by the child. To resolve this problem, a sulphonylurea
suspension called AmglidiaR has demonstratable efficacy in
this indication (43) and has recently obtained a European
Marketing Authorization; it has been available in France under a
temporary authorization for use (ATU: Autorisation Temporaire
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FIGURE 2 | Molecular biology approach to neonatal diabetes (44).
d’Utilization) since 2019. It will enable dosages to be adapted
more accurately.
An Appendix added to this text describes succinctly the
practical aspects of the switch from insulin injection to
the glibenclamide suspension licensed in European Union
for children and refers to the official summary of product
characteristics for detailed information.
Importance of the Genetic Diagnosis
Genetic analyses enables the diagnosis of monogenic diabetes in
nearly 83% of diabetes diagnosed before the age of 6 months (30).
This genetic diagnosis is essential as it will both influence the
therapeutic treatment and make it possible to predict potential
diabetes-related complications or illnesses. Genetic analyses must
be carried out when diagnosing diabetes mellitus in all of the
following children: age <6 months when diabetes mellitus is
detected, or between 6 months and 1 year if extra-pancreatic
features and/or no evidence of pancreas autoimmunity and/or
multiple autoimmune disorders or unusual family history or
associated congenital defects (Figure 2) (44). Testing should
not be delayed until other symptoms of the disease appear or
potential remission of the disease. It is also of utmost importance
to identify if the sulfonylureas can be introduced successfully
as high-dose sulfonylurea therapy has been shown to be an
appropriate treatment for patients with KCNJ11 permanent
neonatal diabetes from diagnosis. This therapy has been shown
to be safe and highly effective, maintaining excellent glycemic
control for at least 10 years (45).
CONCLUSION
Neonatal diabetes is a model of rare human genetic disease,
important in the understanding of the development and
function of the pancreatic β cell, and in helping to resolve
the pathophysiology of more frequent adult diabetes, such
as type 2 diabetes. Neonatal diabetes is often associated
with specific neuropsychological or developmental disorders
of underlying genetic causes. A multidisciplinary approach is
therefore essential. All clinicians called upon to treat a patient
with neonatal diabetes should look for these clinical signs.
Knowing the natural history and complete phenotype of this
disease makes it possible, firstly, to offer patients better treatment
and, secondly, to broaden the scope of genetic analyses to genes
involved in the development and function of other organs.
Long-term follow-up should be implemented, including for the
so-called “transient” forms of neonatal diabetes.
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